Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
8
Next >
Cybin Provides Update on its Intellectual Property Portfolio
October 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
September 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Upcoming Scientific and Investor Conferences
September 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
September 20, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Final Adelia Milestone Achievement
August 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
August 30, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Results of Shareholders’ Meeting
August 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 28, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual Meeting of Shareholders
July 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
July 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
June 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
June 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
June 09, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Acquires DMT Clinical Study from Entheon Biomedical
June 07, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
May 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
May 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
May 05, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit